Navigation Links
Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
Date:6/11/2012

LITTLE ROCK, Ark., June 11, 2012 /PRNewswire-iReach/ -- The Arkansas Prostate Cancer Center, a partnership between AKSM/Oncology and Arkansas Urology, has earned the high honor of a three-year term of accreditation in radiation oncology. The Arkansas Prostate Cancer Center is one of only a handful of prostate-only treatment centers in United States to earn this distinction.

(Photo: http://photos.prnewswire.com/prnh/20120611/CG22394)

The ACR-ASTRO seal of accreditation represents the highest level of quality and patient safety, and is the result of a recent review by the American College of Radiology (ACR) and The American Society for Radiation Oncology (ASTRO). It is awarded only to facilities meeting specific Practice Guidelines and Technical Standards developed by ACR and ASTRO after a peer-review evaluation by board-certified radiation oncologists and medical physicists who are experts in the field.

"Delivering the highest quality of care has always been a priority for the urologists within Arkansas Urology," said Jack Wang, MD. "This accreditation is not required, but we were determined to undergo this vigorous review to assure we delivered the highest quality of care. We firmly believe being recognized with such distinction demonstrates our commitment to quality and excellence, not only to our patients, but to the greater community as well."

During the Arkansas Prostate Cancer Center's review and on-site survey, patient care and treatment, patient safety, personnel qualifications, adequacy of facility equipment, quality control procedures, and quality assurance programs were assessed. The Arkansas Prostate Cancer Center received an unqualified recommendation which means there were no deficiencies that needed improvement.

AKSM/Oncology both manages and staffs the Arkansas Prostate Cancer Center and is the market leader providing radiation therapy services in conjunction with urologists throughout the United States. AKSM/Oncology spent years planning and creating prostate-only treatment centers in partnership with urologists and radiation oncologists to assure the highest clinical standards and protocols were adopted and implemented. "Clinical quality is an ongoing process that requires diligence and commitment of all the parties," said AKSM/Oncology National Clinical Director Donald Jackson. "We applaud ASTRO for continuing to recognize our prostate-only cancer treatment centers for their clinical excellence and highest level of patient care."

Jackson also stated that prostate cancer patients overwhelmingly support treatment at urology-integrated centers like the Arkansas Prostate Cancer Center (click to see videos), and that additional AKSM/Oncology-operated centers are currently seeking ACR accreditation.

The ACR is a national professional organization serving more than 34,000 diagnostic/interventional radiologists, radiation oncologists, nuclear medicine physicians, and medical physicists with programs focusing on the practice of medical imaging and radiation oncology and the delivery of comprehensive health care services. ASTRO is a professional organization serving more than 10,000 radiation oncologists, medical physicists and other health care professionals involved in the treatment of cancer patients.

AKSM/Oncology is a urologist-owned and operated company that has earned a national reputation for its radiation center expertise. AKSM/Oncology, Inc. is a subsidiary of AKSM, Ltd. a national provider of technology and services by urologist for urologists since 1986.

Arkansas Urology is comprised of 17 urologists and 1 radiation oncologist with locations in Little Rock, North Little Rock, Benton, Clinton, El Dorado, Heber Springs, and Russellville. 

Media Contact: Gary Stelluti Health Care Marketing Strategies, LLC, 614-775-9659, gary@hcmarketing.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Arkansas Prostate Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
4. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
7. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
8. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):